DSI
ALDR

Daiwa SB Investments’s Alder Biopharmaceuticals ALDR Stock Holding History

Daiwa SB Investments’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,255
Closed -$117K – 258
2017
Q2 		$117K Sell
10,255
-100
-1% -$1.85K 0.03% 153
2017
Q1 		$215K Sell
10,355
-1,685
-14% -$37.3K 0.06% 122
2016
Q4 		$250K Sell
12,040
-3,960
-25% -$103K 0.07% 119
2016
Q3 		$524K Buy
+16,000
New +$487K 0.14% 107

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Daiwa SB Investments's ALDR Position: Q3 2017 in Review

Daiwa SB Investments sold out of Alder Biopharmaceuticals (ALDR) in Q3 2017, closing a stake of 10,255 shares — an estimated $117K sold.

Daiwa SB Investments first reported a position in ALDR in Q3 2016 and held it in 4 quarters. The position peaked at $524K in Q3 2016. 132 funds tracked by Wall St. Rank hold ALDR as of Q3 2017.

  • Daiwa SB Investments reported no remaining Alder Biopharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Daiwa SB Investments sold 10,255 Alder Biopharmaceuticals shares in Q3 2017, an estimated $117K.
  • Daiwa SB Investments first reported a position in Alder Biopharmaceuticals in Q3 2016 and held it in 4 quarters.
  • Daiwa SB Investments's Alder Biopharmaceuticals position peaked at $524K in Q3 2016.
  • 132 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2017.

Based on Daiwa SB Investments's 13F filing for Q3 2017, filed 13 Oct 2017.